| CAS NO: | 64887-14-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 423.94 |
|---|---|
| Formula | C20H29N5O3.HCl |
| CAS No. | 64887-14-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 24 mg/mL (56.61 mM) |
| Water: 85 mg/mL (200.5 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione monohydrochloride InChi Key: KTMLZVUAXJERAT-UHFFFAOYSA-N InChi Code: InChI=1S/C20H29N5O3.ClH/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3;/h4-5,7-8,15,21H,6,9-14H2,1-3H3;1H SMILES Code: COC1=CC=CC=C1N2CCN(CCCNC3=CC(N(C)C(N3C)=O)=O)CC2.Cl |
| Synonyms | Urapidil hydrochloride |
| In Vitro | In vitro activity: Urapidil hydrochloride is a hydrochloride salt form of urapidil which is α1-adrenoceptor antagonist and 5-HT1A receptor agonist with pIC50 of 6.13 and 6.4 respectively. Urapidil has an alpha-blocking effect but, unlike other alpha-blockers, also has a central sympatholytic effect mediated via stimulation of serotonin 5HT1A receptors in the central nervous system. Urapidil has an alpha-blocking effect but, unlike other alpha-blockers, also has a central sympatholytic effect mediated via stimulation of serotonin 5HT1A receptors in the central nervous system. Several studies have suggested that oral urapidil is effective and well tolerated when used as second-line therapy in patients with BP inadequately controlled with other agents. Urapidil has also been shown to improve glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Naunyn Schmiedebergs Arch Pharmacol. 1987 Dec;336(6):597-601; Adv Ther. 2010 Jul;27(7):426-43. |
m.cnreagent.com